injury-recovery peptides

the most talked-about peptide pair for tendons and joints, and how little is behind it

Read from the entries

computed from each compound's own data at build; nothing here is typed in

Conflictscompatible

1 pairs read: 1 compatible.

BPC-157 + TB-500

Overlap

Places where you may be paying twice for one mechanism.

Peptide class
BPC-157 · TB-500
Tissue repair class
BPC-157 · TB-500

Shared effects

Tissue repair2 of 2

Evidence floor

A stack is only as well supported as its weakest item.

Preclinical

set by TB-500

BPC-15714 papers
TB-5006 papers

Why it works

BPC-157 and TB-500 are injected for tendon, ligament and muscle injuries. The idea is that they work through different routes. In lab and rodent studies BPC-157 promotes blood-vessel growth through VEGFR2 [1] and tendon-cell migration [2]. TB-500 is based on the actin-binding region of Thymosin beta-4 (TB-4), which in its unacetylated form promotes cell migration and wound healing [3].

How they work together

No study has tested this pair. The nearest is a retrospective phone survey in which 4 people had BPC-157 injected into the knee together with full-length thymosin beta-4, not TB-500. Three of the four reported relief [4]. In the one lab study that tested TB-500 directly, the intact peptide did not speed wound closure; one of its breakdown products did [5].

Worth knowing

The evidence card on this page is the point. BPC-157's human data are three small uncontrolled reports [6], and TB-500 has none. Both are unregulated products, and thymosin beta-4 products are banned in sport [7][8].

References

[1]
Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation.
Hsieh MJ, Liu HT, Wang CN et al.J Mol Med (Berl) 2017preclinical · animalPMID 27847966◌ unreviewed
[2]
The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration.
Chang CH, Tsai WC, Lin MS et al.J Appl Physiol (1985) 2011preclinical · cellPMID 21030672◌ unreviewed
[3]
Biological activities of thymosin beta4 defined by active sites in short peptide sequences.
Sosne G, Qiu P, Goldstein AL et al.FASEB J 2010reviewPMID 20179146◌ unreviewed
[4]
Intra-Articular Injection of BPC 157 for Multiple Types of Knee Pain.
Lee E, Padgett BAltern Ther Health Med 2021observational · humanPMID 34324435◌ unreviewed
[5]
Simultaneous quantification of TB-500 and its metabolites in in-vitro experiments and rats by UHPLC-Q-Exactive orbitrap MS/MS and their screening by wound healing activities in-vitro.
Rahaman KA, Muresan AR, Min H et al.J Chromatogr B Analyt Technol Biomed Life Sci 2024preclinical · animalPMID 38382158◌ unreviewed
[6]
Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing.
McGuire FP, Martinez R, Lenz A et al.Curr Rev Musculoskelet Med 2025reviewPMID 40789979◌ unreviewed
[7]
Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review.
Vasireddi N, Hahamyan H, Salata MJ et al.HSS J 2025reviewPMID 40756949◌ unreviewed
[8]
Equine Doping Controls of Thymosin β 4: A Population Study and Strategy for Misuse Detection.
Delcourt V, Garcia P, Chabot B et al.Drug Test Anal 2025other · animalPMID 39314109◌ unreviewed

Not a protocol and not a recommendation to combine anything. Read the individual entries, and talk to a clinician before taking any of this, particularly anything labelled prescription drug.